Final rule 2026-11740
Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The Food and Drug Administration (FDA) is classifying the Spinal Muscular Atrophy newborn screening test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the Spinal Muscular Atrophy newborn screening test system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Source-supplied record
Document details
- Document number
- 2026-11740
- Published
- Jun 11, 2026
- Effective
- Jun 11, 2026
- Comments close
- Not supplied
- Federal Register citation
- 91 FR 35384
Docket identifiers
- Docket No. FDA-2026-N-5828
CFR references
- Title 21, part 866